Publication of prospectus regarding Enzymatica’s rights issue

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, BELARUS, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR INVOLVE REQUIREMENTS FOR MEASURES OTHER THAN WHAT FOLLOWS BY SWEDISH LAW.

The prospectus (the “Prospectus”) for Enzymatica AB’s rights issue of around SEK 130 million (the “Rights issue”) has today been approved and registered by the Swedish Financial Supervisory Authority (Finansinspektionen).

The Prospectus can be obtained from Enzymatica and Hagberg & Aneborn Fondkommission AB (“Hagberg & Aneborn”) and is available on Enzymatica’s website (www.enzymatica.com) and on Hagberg & Aneborn’s website (www.hagberganeborn.se). The Prospectus will also be available on the Swedish Financial Supervisory Authority’s website (www.fi.se). Subscription forms will be available on Enzymatica’s and Hagberg & Aneborn’s websites from August 28, 2024.

Timetable for the Rights issue

Hagberg & Aneborn is Enzymatica’s financial adviser and Setterwalls Advokatbyrå is Enzymatica’s legal adviser in connection with the Rights issue.

For more information, please contact:

Claus Egstrand, CEO, Enzymatica AB

Phone: +44 7780 22 8385 | Email: claus.egstrand@enzymatica.com

Enzymatica AB is headquartered in Lund, Sweden, and is listed on Nasdaq First North Growth Market.

For more information, please visit www.enzymatica.com. Enzymatica’s Certified Adviser is Carnegie Investment Bank AB (publ).